Lv1
10 积分 2025-05-27 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2天前
已完结
SHR-1826, a c-MET directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study
2天前
求助中
Efficacy of thymosin a1 in management of radiation pneumonitisin patients with locally advanced non-small cell lung cancertreated with concurrent chemoradiotherapy: A Phase 2 ClinicalTrial (GASTO-1043)
10天前
已关闭
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Apatinib mesylate in the treatment of advanced triple-negative breast cancer
4个月前
已完结
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
4个月前
已完结
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
5个月前
已完结
皖公网安备34019202002308
